Metabolic pathway modulation by olanzapine: Multitarget approach for treating violent aggression in patients with schizophrenia

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 15, Issue 1

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

All Articles published online

Item

Count

PDF

HTML

201

Figures (1-7)

Tables (1-2)

Sum=313

Publishing Process of This Article

Item

Count

Browse

Download

Sum=62

Jan 19, 2025 (publication date) through Jan 12, 2025

Times Cited of This Article

Journal Information of This Article

Publication Name

World Journal of Psychiatry

ISSN

2220-3206

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Case Control Study

World J Psychiatry. Jan 19, 2025; 15(1): 101186
Published online Jan 19, 2025. doi: 10.5498/wjp.v15.i1.101186

Table 2 Differentially abundant metabolites in patients with schizophrenia treated with olanzapine

No.	Formula	Metabolites	Control group vs pretherapy in the disease group			Control group vs post therapy in the disease group			Adjust
No.	Formula	Metabolites	VIP	Fold change	P value	VIP	Fold change	P value	Adjust
1	C26 H54 N O7 P	Platelet-activating factor	2.09169	0.620166	1.64E-21	1.79868	0.645408	7.75E-19	Reverse
2	C21 H30 O5	Cortisol	1.91193	2.14094	1.21E-17	1.63334	1.72288	2.07E-13	Reverse
3	C18 H40 N O5 P	Dihydrosphingosine 1-phosphate	1.37863	1.79149	1.55E-08	1.11856	1.4172	9.58E-06	Reverse
4	C18 H37 N O2	Palmitoyl ethanolamide	1.70707	1.6449	6.51E-14	1.00437	1.27934	7.33E-06	Reverse
5	C5 H7 N O3	D-(+)-pyroglutamic acid	1.21094	0.586656	9.25E-07	1.06578	0.591467	8.40E-06	Reverse
6	C13 H25 N O3	N-undecanoylglycine	2.20108	4.90093	2.62E-15	1.58901	4.27589	1.64E-09	Reverse
7	C5 H9 N O4	L-glutamic acid	1.9134	0.630722	1.87E-11	1.41269	0.712935	9.56E-08	Reverse
8	C18 H38 N O5 P	Sphingosine 1-phosphate	1.81005	1.38203	4.22E-11	1.45196	1.27835	1.04E-06	Reverse
9	C6 H12 O6	D-(-)-fructose	1.63729	1.77875	6.54E-09	1.25196	1.61936	9.64E-06	Reverse
10	C5 H7 N O3	4-oxoproline	1.54629	0.592293	1.21E-07	1.33034	0.615205	3.25E-06	Reverse

VIP: Variable importance in projection.

Citation: Song YN, Xia S, Sun Z, Chen YC, Jiao L, Wan WH, Zhang HW, Guo X, Guo H, Jia SF, Li XX, Cao SX, Fu LB, Liu MM, Zhou T, Zhang LF, Jia QQ. Metabolic pathway modulation by olanzapine: Multitarget approach for treating violent aggression in patients with schizophrenia. World J Psychiatry 2025; 15(1): 101186
URL: https://www.wjgnet.com/2220-3206/full/v15/i1/101186.htm
DOI: https://dx.doi.org/10.5498/wjp.v15.i1.101186